Agrizy Launches New Phytochemistry R&D Lab for Global Wellness Markets

IMT News Desk
IMT News Desk
· 3 min read
Agrizy launches Phytochemistry R&D Lab for standardized botanical ingredients, targeting $650B nutraceutical market.

Agrizy has launched its Phytochemistry R&D Laboratory, a cutting-edge facility aimed at producing high-performance botanical ingredients and enhancing value flow across India’s herbal supply chain from farm to finished product. Positioned to tap into the $650 billion global nutraceutical market, the lab addresses surging demand for scientifically validated, regulatory-compliant botanicals.

India’s herbal farming communities have long supplied raw materials to the global wellness industry, yet limited value realization at the source due to fragmented procurement, price-driven aggregation, and inconsistent quality has restricted farmers’ access to premium markets. As global nutraceutical demand prioritizes provenance, safety, clinical validation, and transparency, Agrizy’s initiative bridges this gap.

“This investment enhances our capability to develop scientifically validated herbal ingredients that comply with global standards and deliver consistent performance. By combining traditional botanical knowledge with advanced research, extraction technologies, and strong quality systems, we are creating standardized ingredients that meet international expectations. This demonstrates our commitment to establishing credibility and long-term value within the nutraceutical ecosystem,” said Dr. S. Vijaya Kumar, CEO, Wellness, Agrizy.

Equipped with advanced laboratory instruments, the facility extracts, isolates, and purifies phyto-ingredients from medicinal plants, focusing on development, raw material authentication, and herbal extract standardization. A key differentiator is phytochemical evaluation, with multi-stage fingerprinting and method validation per United States Pharmacopoeia (USP) and international benchmarks, ensuring reproducible potency and purity claims.

The lab pioneers advanced delivery systems like phytosomes, nanoformulations, and water-soluble formats to boost absorption, stability, and performance in capsules, tablets, functional beverages, and nutraceutical foods.

Led by Dr. Laxman Sawant (PhD in Phytochemistry, 16+ years at Dabur, Himalaya, Piramal, Natural Remedies, and OmniActive), the team brings over 100 years of combined expertise in botanical research, analytical chemistry, formulation, and regulatory affairs.

Agrizy partners with farmers, Farmer Producer Organisations (FPOs), and Village Level Aggregators (VLAs) in Karnataka, Maharashtra, Tamil Nadu, and West Bengal hubs for turmeric, coleus, bacopa, and ashwagandha. Its sourcing model sets phytochemical and marker-based specs at the farm level, blending Ayurvedic pharmacognosy with modern validation for quality-controlled pipelines, stable premium demand, traceability, and reduced adulteration.

This stakeholder-aligned approach benefits farmers with higher-value demand, brands with compliant ingredients, and markets with traceable, research-backed products. Agrizy holds 21 trademarks, two patents (more filings), and targets high-demand botanicals like Curcumin (inflammation/metabolic health), Ashwagandha (adaptogenic/cognitive), Boswellia (joint health), Bacopa, and Gymnema. Early Curcumin and Coleus initiatives are commercializing now.

Regulatory integration supports FSSAI, AYUSH, US FDA, and EFSA compliance via complete technical dossiers, shortening development cycles to 3-6 months from concept to market.

Read Next

PM Modi to Dedicate Key Healthcare Infrastructure Projects to Nation on July 17: PGIMER Director
News
July 14, 2026

PM Modi to Dedicate Key Healthcare Infrastructure Projects to Nation on July 17: PGIMER Director

Prime Minister Narendra Modi will dedicate several key healthcare infrastructure projects to the nation on July 17, according to PGIMER Director Dr Vivek Lal. The projects include the Advanced Mother and Child Centre, the Advanced Neurosciences Centre and a new Critical Care Block, all of which are expected to strengthen tertiary care services and expand […]
Article by: IMT News Desk
OneSource Specialty Pharma and Formycon AG Announce Strategic Manufacturing Partnership for Biosimilars
News
July 14, 2026

OneSource Specialty Pharma and Formycon AG Announce Strategic Manufacturing Partnership for Biosimilars

OneSource Specialty Pharma Limited and Formycon AG have announced a strategic manufacturing partnership for biosimilars, bringing together Formycon’s biosimilar development expertise and OneSource’s integrated biologics manufacturing capabilities to support global markets. Under the agreement, OneSource will serve as a strategic manufacturing partner for Formycon and provide both drug substance and drug product manufacturing from its […]
Article by: IMT News Desk
FDA Approves At-Home Starter Dose of Eisai-Biogen’s Alzheimer’s Drug Leqembi
News
July 14, 2026

FDA Approves At-Home Starter Dose of Eisai-Biogen’s Alzheimer’s Drug Leqembi

The U.S. Food and Drug Administration has approved an at-home starting dose of Eisai and Biogen’s Alzheimer’s drug Leqembi, allowing some patients to begin treatment with injections administered by themselves or a caregiver. The decision expands access to the drug’s subcutaneous formulation, which can now be used as a starter dose rather than only after […]
Article by: IMT News Desk
Emcure Pharmaceuticals Consolidates Full Ownership of Gennova Amid Leadership Transition
News
July 14, 2026

Emcure Pharmaceuticals Consolidates Full Ownership of Gennova Amid Leadership Transition

Emcure Pharmaceuticals Limited has announced the consolidation of its shareholding in biopharma subsidiary Gennova Biopharmaceuticals Limited, alongside a leadership transition, as it sharpens its focus on biologics and biosimilars. The company is acquiring the entire 12.05% minority stake in Gennova held by Dr Sanjay Singh and others, taking its ownership to 100% and making Gennova […]
Article by: IMT News Desk